Updated as of November 4, 2026

Revolution Medicines Clinical Development Pipeline

Phase 3 Registrational Trials

	Molecule	Target	Trial	Treatment Setting	Regimen	Status
PDAC	RASONQUE® (daraxonrasib)	MULTI	RASolute 302	2L metastatic	Mono	Completed*
PDAC	Daraxonrasib	MULTI	RASolute 303	1L metastatic	Mono & Combo	Ongoing
PDAC	Daraxonrasib	MULTI	RASolute 304	Adjuvant in resectable	Mono	Ongoing
PDAC	Zoldonrasib	G12D	RASolute 305	1L metastatic	Combo	Ongoing
PDAC	Daraxonrasib + Zoldonrasib	G12D	RASolute 309	1L metastatic	Combo	Ongoing
NSCLC	Daraxonrasib	MULTI	RASolve 301	2L/3L metastatic	Mono	Ongoing
NSCLC	Zoldonrasib	G12D	RASolve 308	1L metastatic	Combo	Ongoing
NSCLC	Elironrasib	G12C	RASolve 307	1L metastatic	Combo	Ongoing
CRC	Zoldonrasib	G12D	RASonate 312 [1]	1L metastatic	Combo	Initiating

Phase 1/2 Clinical Development

RASONQUE® (daraxonrasib) is approved in the U.S. and is also being evaluated in other settings, where it remains investigational. Zoldonrasib (G12D), elironrasib (G12C), and RMC-5127 (G12V) are being evaluated in solid tumors across a range of monotherapy and combination treatment strategies. RM-055, a mutant-targeted catalytic RAS(ON) inhibitor, is currently advancing through IND-enabling studies. For more information, visit ClinicalTrials.gov.

1L, first line; 2L, second line; 3L, third line; NSCLC, non-small cell lung cancer; PDAC, pancreatic adenocarcinoma

The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.

*RASONQUE is approved in the U.S. for adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy. It is also being evaluated in other settings, where it remains investigational.

(1) BeOne Medicines is funding and conducting RASonate 312 as part of its collaboration with Revolution Medicines.